TG Therapeutics (NASDAQ: TGTX) is a clinical-stage biopharmaceutical company with a focus on the development and commercialization of new, highly innovative therapies for the treatment of multiple cancers. Specifically, the company is developing two therapies targeting hematological malignancies, specifically, relapsed, and refractory non-Hodgkins lymphoma, as well as additional medical indications like multiple sclerosis (NYSE:MS).
